18889881171
Kalkine 0
countryflagUS

Biotricity Inc

Healthcare US BTCY

0.52USD
-(-%)

Last update at 2025-05-22T15:04:00Z

Day Range

0.520.52
LowHigh

52 Week Range

0.704.37
LowHigh

Fundamentals

  • Previous Close 0.52
  • Market Cap10.89M
  • Volume300
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.23159M
  • Revenue TTM11.63M
  • Revenue Per Share TTM1.32
  • Gross Profit TTM 4.57M
  • Diluted EPS TTM-1.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -18.65814M -29.13048M -15.49118M -11.06694M -8.59206M
Minority interest - - - - -
Net income -19.53368M -30.21945M -16.45332M -11.32487M -8.59206M
Selling general administrative 17.62M 19.85M 12.81M 10.26M 7.46M
Selling and marketing expenses - - - - -
Gross profit 5.44M 4.57M 1.51M 0.69M 0.15M
Reconciled depreciation 0.00595M 0.00231M - - -
Ebit -15.40971M -16.73680M -16.45332M -11.32487M -8.59206M
Ebitda -15.40376M -16.73449M -3.74151M -0.65797M -0.01167M
Depreciation and amortization 0.00595M 0.00231M 12.71M 10.67M 8.58M
Non operating income net other - - 0.37M - -
Operating income -15.40971M -16.73680M -12.71181M -10.66690M -8.58040M
Other operating expenses 25.05M 25.67M 16.74M 12.35M 8.99M
Interest expense 2.58M 9.29M 1.80M 0.09M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income -2.58262M -9.28602M -2.48116M -0.09242M 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 875.54M 1.09M -2.77936M -0.40004M -0.01167M
Total revenue 9.64M 7.65M 3.38M 1.42M 0.40M
Total operating expenses 20.85M 22.59M 14.87M 11.62M 8.74M
Cost of revenue 4.20M 3.08M 1.87M 0.73M 0.25M
Total other income expense net -3.24843M -12.39367M -2.77936M -0.40004M -0.01167M
Discontinued operations - - - - -
Net income from continuing ops -18.65814M -29.13048M -15.49118M -11.06694M -8.59206M
Net income applicable to common shares - -30.21945M -16.45332M -11.32487M -8.59206M
Preferred stock and other adjustments - - 0.96M - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 6.51M 16.68M 4.44M 2.00M 0.49M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 588.60M 0.41M 0.33M 0.14M 0.10M
Total liab 26.36M 18.82M 11.27M 5.00M 2.27M
Total stockholder equity -19.84539M -2.14474M -6.83316M -3.00039M -1.77768M
Deferred long term liab - - 0.41M - -
Other current liab 1.01M 1.96M 3.63M 0.43M 0.52M
Common stock 0.05M 0.05M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.05M 0.04M 0.04M 0.04M
Retained earnings -112.57082M -93.03714M -62.81769M -46.36436M -35.03950M
Other liab - 0.35M 0.41M - -
Good will - - - - -
Other assets - 0.09M 0.05M 0.08M 0.03M
Cash 0.57M 12.07M 2.20M 0.95M 0.06M
Cash and equivalents - - - - -
Total current liabilities 11.16M 4.87M 10.49M 3.80M 2.27M
Current deferred revenue 1.61M - 1.48M - -
Net debt 18.98M 3.29M 2.51M 1.39M 0.80M
Short term debt 5.11M 1.75M 4.34M 2.28M 0.87M
Short long term debt 4.77M 1.54M 4.28M 2.07M 0.87M
Short long term debt total 19.55M 15.35M 4.71M 2.34M 0.87M
Other stockholder equity 92.83M 91.61M 56.58M 44.18M 33.98M
Property plant equipment - 1.27M 0.07M 0.26M -
Total current assets 4.72M 15.32M 4.32M 1.66M 0.46M
Long term investments - - - - -
Net tangible assets - -2.14474M -6.83317M -3.00040M -1.77768M
Short term investments - - - - 0.10M
Net receivables 1.81M 2.01M 1.52M 0.49M 0.27M
Long term debt 13.05M 12.48M 0.37M - -
Inventory 2.34M 0.84M 0.27M 0.09M 0.02M
Accounts payable 3.44M 1.16M 1.04M 1.09M 0.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.15280M -0.76866M -0.63419M -0.85731M -0.75496M
Additional paid in capital - - - - -
Common stock total equity - - 0.04M 0.04M 0.04M
Preferred stock total equity - - 0.00001M - -
Retained earnings total equity - - -62.81769M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.18M 0.09M 0.05M 0.08M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 1.79M 1.36M 0.12M 0.35M 0.03M
Capital lease obligations 1.72M 1.33M 0.06M 0.27M -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments 0.00000M -0.02977M - - -
Change to liabilities - 0.95M 0.75M 0.08M 0.65M
Total cashflows from investing activities - -0.02977M -0.02977M -0.02977M -0.02977M
Net borrowings - 10.60M 12.54M 1.20M 0.87M
Total cash from financing activities 2.00M 25.17M 12.20M 8.88M 4.56M
Change to operating activities - -0.06066M -0.15659M 0.03M -0.11290M
Net income -18.65814M -29.13048M -15.49118M -11.06694M -8.59206M
Change in cash -11.49647M 9.87M 1.25M 0.89M -0.78000M
Begin period cash flow 12.07M 2.20M 0.95M 0.06M 0.84M
End period cash flow 0.57M 12.07M 2.20M 0.95M 0.06M
Total cash from operating activities -13.54794M -15.16338M -11.08083M -7.86278M -5.22085M
Issuance of capital stock 0.00000M 14.90M 0.20M 7.86M 3.64M
Depreciation 0.00595M 0.00231M 2.48M 0.15M 0.15M
Other cashflows from investing activities - - - - -
Dividends paid -0.94678M -0.96611M -0.60297M -0.18000M 0.18M
Change to inventory -1.49408M -0.57043M -0.18677M -0.06112M -0.02460M
Change to account receivables 0.69M -0.43548M -1.03689M -0.32620M -0.20810M
Sale purchase of stock -0.89556M -0.23000M 0.27M - -
Other cashflows from financing activities 3.84M 13.23M 13.21M 9.03M 0.92M
Change to netincome - 4.80M 1.71M 3.49M 3.06M
Capital expenditures 0.00000M 0.03M 0.03M 0.03M 0.03M
Change receivables - - -1.19348M - -
Cash flows other operating - - 0.84M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 1.12M - -
Change in working capital 2.31M -0.11758M -0.62790M -0.28651M 0.31M
Stock based compensation 0.65M 0.91M 0.79M 2.41M 1.45M
Other non cash items 2535.73M 13.17M 4.25M 1.08M 1.61M
Free cash flow -13.54794M -15.19315M -11.08083M -7.86278M -5.22085M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BTCY
Biotricity Inc		 - -% 0.52 - - 0.94 33.02 2.96 -3.5958
ABT
Abbott Laboratories		 -1.34 1.01% 131.71 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -2.5 0.66% 377.25 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -3.18 3.77% 81.23 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.4 0.38% 104.24 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Biotricity Inc

203 Redwood Shores Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Dr. Waqaas Al-Siddiq Ph.D. Founder, Pres, CEO & Chairman 1985
Mr. S. John Ayanoglou Chief Financial Officer 1966
Dr. George N. Nikopoulos Director of Bus. Devel. NA
Mr. Amir Ali Chief Devel. Officer NA
Dr. Waqaas Al-Siddiq Ph.D. Founder, President, CEO & Chairman 1985
Mr. S. John Ayanoglou Chief Financial Officer 1967
Mr. Andy Wong Vice President of Operations NA
Dr. George N. Nikopoulos Director of Business Development NA
Mr. Matt Zabel Vice President of Sales & Strategy NA
Mr. Amir Ali Chief Development Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.